Actinium Pharmaceuticals, Inc. (ATNM) SEC Filing 10-Q Quarterly Report for the period ending Friday, March 31, 2023

In determining whether goods or services are distinct, we evaluate certain criteria, including whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and (ii) the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the contract).

The commercial opportunity is supported by favorable dynamics, summarized by the "Three Ps and Two Cs": Patients: With its promising profile, Iomab-B provides the opportunity for unprecedented BMT access and better outcomes for patients, with favorable safety and tolerability Physicians: Our goal is to help physicians make BMT an option for a vast majority of r/r AML patients who currently are unable to access transplant without disruption to current practice.